Clinical Trial

Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients

Study acronym: PRARE-CHB
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 10, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to determine the prevalence of antiviral drug resistance among Egyptian patients with chronic hepatitis B virus (HBV) infection and to identify the associated demographic, clinical, and virological risk factors. Understanding patterns of resistance will help improve treatment selection and optimize long-term management strategies for HBV patients.
Trial Details
NCT Number NCT07274345
Lead Sponsor Amira Mohamed Zidan
Conditions Chronic Hepatitis B - Antiviral Drug Resistance - Hepatitis B Virus (HBV) Infection
Enrollment 2,000 participants
Start Date 2025-12-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-10